392 related articles for article (PubMed ID: 34559410)
1. Abiraterone acetate versus nonsteroidal antiandrogen with androgen deprivation therapy for high-risk metastatic hormone-sensitive prostate cancer.
Yanagisawa T; Kimura T; Mori K; Suzuki H; Sano T; Otsuka T; Iwamoto Y; Fukuokaya W; Miyajima K; Enei Y; Sakanaka K; Matsukawa A; Onuma H; Obayashi K; Tsuzuki S; Hata K; Shimomura T; Miki J; Egawa S
Prostate; 2022 Jan; 82(1):3-12. PubMed ID: 34559410
[TBL] [Abstract][Full Text] [Related]
2. Abiraterone acetate versus bicalutamide in combination with gonadotropin releasing hormone antagonist therapy for high risk metastatic hormone sensitive prostate cancer.
Ueda T; Shiraishi T; Ito S; Ohashi M; Matsugasumi T; Yamada Y; Fujihara A; Hongo F; Okihara K; Ukimura O
Sci Rep; 2021 May; 11(1):10094. PubMed ID: 33980956
[TBL] [Abstract][Full Text] [Related]
3. Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol.
Attard G; Murphy L; Clarke NW; Cross W; Jones RJ; Parker CC; Gillessen S; Cook A; Brawley C; Amos CL; Atako N; Pugh C; Buckner M; Chowdhury S; Malik Z; Russell JM; Gilson C; Rush H; Bowen J; Lydon A; Pedley I; O'Sullivan JM; Birtle A; Gale J; Srihari N; Thomas C; Tanguay J; Wagstaff J; Das P; Gray E; Alzoueb M; Parikh O; Robinson A; Syndikus I; Wylie J; Zarkar A; Thalmann G; de Bono JS; Dearnaley DP; Mason MD; Gilbert D; Langley RE; Millman R; Matheson D; Sydes MR; Brown LC; Parmar MKB; James ND;
Lancet; 2022 Jan; 399(10323):447-460. PubMed ID: 34953525
[TBL] [Abstract][Full Text] [Related]
4. Comparison of clinical outcomes between androgen deprivation therapy with up-front abiraterone and bicalutamide for Japanese patients with LATITUDE high-risk prostate cancer in a real-world retrospective analysis.
Naiki T; Takahara K; Ito T; Nakane K; Sugiyama Y; Koie T; Shiroki R; Miyake H; Yasui T
Int J Clin Oncol; 2022 Mar; 27(3):592-601. PubMed ID: 34779958
[TBL] [Abstract][Full Text] [Related]
5. Combination of docetaxel versus nonsteroidal antiandrogen with androgen deprivation therapy for high-volume metastatic hormone-sensitive prostate cancer: a propensity score-matched analysis.
Yanagisawa T; Kimura T; Hata K; Narita S; Hatakeyama S; Mori K; Sano T; Otsuka T; Iwamoto Y; Enei Y; Nakazono M; Sakanaka K; Iwatani K; Matsukawa A; Atsuta M; Nishikawa H; Tsuzuki S; Miki J; Habuchi T; Ohyama C; Shariat SF; Egawa S
World J Urol; 2023 Aug; 41(8):2051-2062. PubMed ID: 35596809
[TBL] [Abstract][Full Text] [Related]
6. Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial.
Fizazi K; Tran N; Fein L; Matsubara N; Rodriguez-Antolin A; Alekseev BY; Özgüroğlu M; Ye D; Feyerabend S; Protheroe A; Sulur G; Luna Y; Li S; Mundle S; Chi KN
Lancet Oncol; 2019 May; 20(5):686-700. PubMed ID: 30987939
[TBL] [Abstract][Full Text] [Related]
7. Abiraterone acetate in combination with androgen deprivation therapy compared to androgen deprivation therapy only for metastatic hormone-sensitive prostate cancer.
Sathianathen NJ; Oestreich MC; Brown SJ; Gupta S; Konety BR; Dahm P; Kunath F
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013245. PubMed ID: 33314020
[TBL] [Abstract][Full Text] [Related]
8. Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer.
Fizazi K; Tran N; Fein L; Matsubara N; Rodriguez-Antolin A; Alekseev BY; Özgüroğlu M; Ye D; Feyerabend S; Protheroe A; De Porre P; Kheoh T; Park YC; Todd MB; Chi KN;
N Engl J Med; 2017 Jul; 377(4):352-360. PubMed ID: 28578607
[TBL] [Abstract][Full Text] [Related]
9. Patient-reported outcomes following abiraterone acetate plus prednisone added to androgen deprivation therapy in patients with newly diagnosed metastatic castration-naive prostate cancer (LATITUDE): an international, randomised phase 3 trial.
Chi KN; Protheroe A; Rodríguez-Antolín A; Facchini G; Suttman H; Matsubara N; Ye Z; Keam B; Damião R; Li T; McQuarrie K; Jia B; De Porre P; Martin J; Todd MB; Fizazi K
Lancet Oncol; 2018 Feb; 19(2):194-206. PubMed ID: 29326030
[TBL] [Abstract][Full Text] [Related]
10. Rezvilutamide versus bicalutamide in combination with androgen-deprivation therapy in patients with high-volume, metastatic, hormone-sensitive prostate cancer (CHART): a randomised, open-label, phase 3 trial.
Gu W; Han W; Luo H; Zhou F; He D; Ma L; Guo H; Liang C; Chong T; Jiang J; Chen Z; Wang Y; Zou Q; Tian Y; Xiao J; Huang J; Zhu S; Dong Q; Zhang X; Li H; Yang X; Chen C; Li J; Jin C; Zhang X; Ye D;
Lancet Oncol; 2022 Oct; 23(10):1249-1260. PubMed ID: 36075260
[TBL] [Abstract][Full Text] [Related]
11. [Early- vs. late-onset treatment using abiraterone acetate plus prednisone in chemo-naïve, asymptomatic or mildly symptomatic patients with metastatic CRPC after androgen deprivation therapy].
Merseburger AS; Rüssel C; Belz H; Spiegelhalder P; Feyerabend S; Tran N; Kruetzfeldt K; Baurecht W; Bögemann M
Aktuelle Urol; 2020 Dec; 51(6):562-571. PubMed ID: 32268436
[TBL] [Abstract][Full Text] [Related]
12. Hot flashes during androgen deprivation therapy with luteinizing hormone-releasing hormone agonist combined with steroidal or nonsteroidal antiandrogen for prostate cancer.
Sakai H; Igawa T; Tsurusaki T; Yura M; Kusaba Y; Hayashi M; Iwasaki S; Hakariya H; Hara T; Kanetake H
Urology; 2009 Mar; 73(3):635-40. PubMed ID: 19038426
[TBL] [Abstract][Full Text] [Related]
13. Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy.
James ND; de Bono JS; Spears MR; Clarke NW; Mason MD; Dearnaley DP; Ritchie AWS; Amos CL; Gilson C; Jones RJ; Matheson D; Millman R; Attard G; Chowdhury S; Cross WR; Gillessen S; Parker CC; Russell JM; Berthold DR; Brawley C; Adab F; Aung S; Birtle AJ; Bowen J; Brock S; Chakraborti P; Ferguson C; Gale J; Gray E; Hingorani M; Hoskin PJ; Lester JF; Malik ZI; McKinna F; McPhail N; Money-Kyrle J; O'Sullivan J; Parikh O; Protheroe A; Robinson A; Srihari NN; Thomas C; Wagstaff J; Wylie J; Zarkar A; Parmar MKB; Sydes MR;
N Engl J Med; 2017 Jul; 377(4):338-351. PubMed ID: 28578639
[TBL] [Abstract][Full Text] [Related]
14. Docetaxel versus abiraterone for metastatic hormone-sensitive prostate cancer with focus on efficacy of sequential therapy.
Yanagisawa T; Hata K; Narita S; Hatakeyama S; Mori K; Yata Y; Sano T; Otsuka T; Hara S; Miyajima K; Enei Y; Fukuokaya W; Nakazono M; Matsukawa A; Miki J; Habuchi T; Ohyama C; Shariat SF; Kimura T
Prostate; 2023 May; 83(6):563-571. PubMed ID: 36661102
[TBL] [Abstract][Full Text] [Related]
15. Predictive factors for the efficacy of abiraterone acetate therapy in high-risk metastatic hormone-sensitive prostate cancer patients.
Ueda T; Fujita K; Nishimoto M; Shiraishi T; Miyashita M; Kayukawa N; Nakamura Y; Sako S; Ogura R; Fujihara A; Minami T; Hongo F; Okihara K; Yoshimura K; Uemura H; Ukimura O
World J Urol; 2022 Dec; 40(12):2939-2946. PubMed ID: 36331614
[TBL] [Abstract][Full Text] [Related]
16. A randomised, double-blind study comparing the addition of bicalutamide with or without dutasteride to GnRH analogue therapy in men with non-metastatic castrate-resistant prostate cancer.
Chu FM; Sartor O; Gomella L; Rudo T; Somerville MC; Hereghty B; Manyak MJ
Eur J Cancer; 2015 Aug; 51(12):1555-69. PubMed ID: 26048455
[TBL] [Abstract][Full Text] [Related]
17. Bicalutamide 150 mg as secondary hormonal therapy for castration-resistant prostate cancer.
Qian SB; Shen HB; Cao QF; Zhang L; Chen YF; Qi J
Int Urol Nephrol; 2015 Mar; 47(3):479-84. PubMed ID: 25665794
[TBL] [Abstract][Full Text] [Related]
18. Prior switching to a second-line nonsteroidal antiandrogen does not impact the therapeutic efficacy of abiraterone acetate in patients with metastatic castration-resistant prostate cancer: a real-world retrospective study.
Zhao JG; Liu JD; Shen PF; Tang X; Sun GX; Zhang XM; Chen JR; Shu KP; Shi M; Zeng H
Asian J Androl; 2018; 20(6):545-550. PubMed ID: 30106011
[TBL] [Abstract][Full Text] [Related]
19. Epigenetic Therapy with Panobinostat Combined with Bicalutamide Rechallenge in Castration-Resistant Prostate Cancer.
Ferrari AC; Alumkal JJ; Stein MN; Taplin ME; Babb J; Barnett ES; Gomez-Pinillos A; Liu X; Moore D; DiPaola R; Beer TM
Clin Cancer Res; 2019 Jan; 25(1):52-63. PubMed ID: 30224345
[TBL] [Abstract][Full Text] [Related]
20. Comparative effectiveness of multiple androgen receptor signaling inhibitor medicines with androgen deprivation therapy for metastatic hormone-sensitive prostate cancer: a study in the real world.
Lu Y; Jiang J; Yang G; Ding H; Zheng Q; Ji L; Wang Y; Dong Z; Zhai Z; Tian J; Zhang Y; Wang J; Yang L; Wang Z
Front Oncol; 2024; 14():1324181. PubMed ID: 38699643
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]